BIOCRYST PHARMACEUTICALS INC (BCRX)
US09058V1035 - Common Stock
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -123.82M | -226.54M | -247.12M | -184.06M | -182.81M | |||
| Depreciation Amortization | 1.36M | 1.66M | 1.44M | 780.00K | 750.00K | |||
| Change In Working Capital | -57.85M | -32.40M | -58.95M | 8.12M | 26.88M | |||
| Interest Paid | N/A | 22.14M | N/A | N/A | N/A | |||
| Taxes Paid | N/A | 1.43M | N/A | N/A | N/A | |||
| Other non cash items | 124.59M | 162.14M | 142.77M | 33.00M | 20.08M | |||
| OPERATING CASH FLOW | -55.73M | -95.14M | -161.85M | -142.16M | -135.11M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -1.01M | -2.17M | -1.35M | -2.39M | -510.00K | |||
| Other Investing Activity | 7.32M | -129.33M | -126.89M | 18.19M | -6.34M | |||
| INVESTING CASH FLOW | 6.33M | -131.50M | -128.24M | 15.80M | -6.86M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -2.52M | 58.38M | 73.07M | 293.87M | 190.05M | |||
| Stock Issued/Repurchased | 4.22M | 8.68M | 14.96M | 65.79M | 110.54M | |||
| Other Financing Activity | -6.62M | -34.58M | N/A | N/A | N/A | |||
| FINANCING CASH FLOW | -4.92M | 32.48M | 88.03M | 359.67M | 300.59M | |||
| Exchange Rate Effect | 890.00K | 362.00K | 570.00K | 70.00K | N/A | |||
| CHANGE IN CASH | -53.42M | -193.79M | -201.49M | 233.38M | 158.62M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -55.73M | -95.14M | -161.85M | -142.16M | -135.11M | |||
| Capital Expenditure | -1.01M | -2.17M | -1.35M | -2.39M | -510.00K | |||
| FREE CASH FLOW | -56.74M | -97.31M | -163.20M | -144.55M | -135.62M | |||
All data in USD